Infex Therapeutics

Infex Therapeutics, also known as InfexTx, describes itself as a leading anti-infectives specialist. It acquires, develops, and licenses innovative drugs to treat pandemic infections, and states that it has expanded to develop a broader portfolio of new therapies addressing the rising burden of critical priority infectious disease. The company is based at Alderley Park in the North West of England, and its work is aimed at unmet patient needs, bringing a new portfolio of drugs into clinical trials to treat patients suffering from life-threatening infections.

Infex Therapeutics, also known as InfexTx, is based at Alderley Park in the North West of England. It acquires, develops, and licenses innovative drugs to treat pandemic infections, and states that it has expanded to develop a broader portfolio of new therapies to meet the rising burden of critical priority infectious disease. Its work addresses unmet patient needs and aims to bring a new portfolio of drugs into clinical trials to treat patients suffering from life-threatening infections. The company has presented Phase IIa data for RESP-X, including at ERS Congress 2026, and has made a written submission to the Presidential Advisory Council on Combating Antibiotics.

Self-described leading anti-infectives specialist focused on pandemic infections and critical priority infectious disease.

• RESP-X

  A therapy studied in a Phase IIa trial in Pseudomonas aeruginosa-colonised non-cystic fibrosis bronchiectasis (NCFB) patients.

1. 1Infex Therapeutics – Vital new drugs for pandemic infectionsinfextx.com